Search

Your search keyword '"Steg, Ph. Gabriel"' showing total 902 results

Search Constraints

Start Over You searched for: Author "Steg, Ph. Gabriel" Remove constraint Author: "Steg, Ph. Gabriel"
902 results on '"Steg, Ph. Gabriel"'

Search Results

202. Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding

204. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention

205. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes

206. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease : An analysis from the platelet inhibition and patient outcomes (plato) trial

207. Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST

208. Abstract 18632: Variation in Patient Profiles and Outcomes in US and non-US Subgroups of the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial

209. Predictors of Long‐term Adherence to Evidence‐based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry

210. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk.

211. Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease.

214. Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure

215. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy

216. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX

219. Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up

221. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials

222. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes

223. Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin

224. Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

225. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study

226. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

228. Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT Trial.

230. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.

233. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

234. High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events

236. Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention

237. Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization

238. NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease

241. Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes)

242. Outcomes and excess costs among patients with cardiovascular disease

243. 2013 ESC guidelines on the management of stable coronary artery disease:The Task Force on the management of stable coronary artery disease of the European Society of Cardiology

244. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience

245. Response to Letter Regarding Article, 'Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO'

246. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation : the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

247. Third universal definition of myocardial infarction

248. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial.

249. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

250. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial:insights from the ECG substudy

Catalog

Books, media, physical & digital resources